Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 in Attenuated Psychosis Syndrome
NCT03230097Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of osoresnontrine in attenuated psychosis syndrome (APS), sponsored by Boehringer Ingelheim. Started Sep 2017; status: terminated.
02
Drugs
osoresnontrine
03
Conditions
attenuated psychosis syndrome (APS)
Beyond the preview
Go deeper on NCT03230097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230097.